Food and Drug Administration staff cuts may hinder US biomedical innovation
The elimination of 3,500 full-time employees at the FDA risks undermining the very innovation and domestic capacity the president seeks to promote, and could lead to a loss of American capital, investment and jobs.
.png?Expires=1838763821&Key-Pair-Id=K2ZIVPTIP2VGHC&Signature=IO0~CT3pU-TcxGc~yoZSmoQx23MZVuK-~4jSii~NKEblRmyO3el7NXPu~Rh1o23voASg7hlcHLw4kvQuDK1jssEhcjoNBBvEpZ~GGOAU6yosBhpHpeF179F~h7i6VxmsBNh9gtTutkoqY73O2YCFey~IAqSzKbBqETP1kP9cAg1916Z1YkJJs-5MliMrkZ5d7-mWGLbpHp2wGj2VlMph8XzYlL4~y1O7fB~JdIS~Rs4RMRs2x0WT1qUIpHAsf3GdwtOyAmKFSpIg8xCyNGZZ5h~13nXlmpd7uPvW8tBfttpG9pFTqcway-uch5WyfHOEfi7UlJCOWrr6fCYY5PMgSg__)
